A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Eligible age
18+ yrs
Accepts
All genders
Locations
29 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Sponsor: AstraZeneca
Where it's recruiting
Daphne
Springdale
Duarte · Fountain Valley · Glendale · Sacramento …
Aurora · Denver
New Haven
Altamonte Springs · Jacksonville · Miami · Palm Bay …
Atlanta
Honolulu
Chicago · Decatur · Elmhurst · Naperville
New Albany
Des Moines
Lexington · Louisville
Source: ClinicalTrials.gov · NCT06103864 · last updated 2026-11-20